T1	PROC 87 98	TRATAMIENTO
#1	AnnotatorNotes T1	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T2	PROC 131 140	PROTOCOLO
#2	AnnotatorNotes T2	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T3	PROC 141 215	ENSAYO CLÍNICO FASE III ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO
T4	CHEM 44 66	INMUNOGLOBULINA HUMANA
T5	PROC 262 273	TRATAMIENTO
#3	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	DISO 347 366	abortos recurrentes
#4	AnnotatorNotes T6	C0000809; Abortion, Habitual; Disease or Syndrome
T7	DISO 392 411	abortos recurrentes
#5	AnnotatorNotes T7	C0000809; Abortion, Habitual; Disease or Syndrome
T8	PROC 563 573	evaluación
#6	AnnotatorNotes T8	C1261322; Evaluation procedure; Health Care Activity
T9	PROC 576 588	intervención
#7	AnnotatorNotes T9	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T10	DISO 627 646	abortos espontáneos
#8	AnnotatorNotes T10	C0000786; Spontaneous abortion; Pathologic Function
T11	ANAT 747 757	Células NK
#9	AnnotatorNotes T11	C0022688; Natural Killer Cells; Cell
T12	PROC 918 936	linfocitos totales
T13	ANAT 824 834	linfocitos
#10	AnnotatorNotes T13	C0024264; Lymphocyte; Cell
T14	PROC 894 905	células NKT
T15	ANAT 918 928	linfocitos
#11	AnnotatorNotes T15	C0024264; Lymphocyte; Cell
T16	PROC 783 797	CD3-CD56+CD16+
#12	AnnotatorNotes T16	C5188571; CD3-CD16+CD56+ cells in blood; Laboratory Procedure
T17	CHEM 1142 1152	medicación
#13	AnnotatorNotes T17	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T18	DISO 1194 1211	hipersensibilidad
#14	AnnotatorNotes T18	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T19	DISO 1288 1318	Enfermedades inmunodeficientes
T20	DISO 1231 1251	Infección bacteriana
#15	AnnotatorNotes T20	C0004623; Bacterial Infections; Disease or Syndrome
T21	DISO 1336 1351	Hepatitis B o C
T22	PROC 1358 1366;1376 1401	antígeno hepatitis B de superficie
#16	AnnotatorNotes T22	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T23	DISO 1376 1387	hepatitis B
#17	AnnotatorNotes T23	C0019163; Hepatitis B; Disease or Syndrome
T24	PROC 1403 1408	HBsAg
#18	AnnotatorNotes T24	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T25	DISO 1428 1439	hepatitis C
#19	AnnotatorNotes T25	C0019196; Hepatitis C; Disease or Syndrome
T26	PROC 1446 1453	cribado
#20	AnnotatorNotes T26	C0220908; Screening procedure; Diagnostic Procedure | C1710031; Disease Screening; Diagnostic Procedure
T27	DISO 1477 1493	Abuso de alcohol
T28	PROC 1574 1588	ensayo clínico
#21	AnnotatorNotes T28	C0008976; Clinical Trials; Research Activity
T29	CHEM 1596 1620	medicamento experimental
#22	AnnotatorNotes T29	C0304229; Experimental drug; Pharmacologic Substance
T30	DISO 103 109	ABORTO
#23	AnnotatorNotes T30	C0156543; Unspecified Abortion; Finding
T31	CHEM 219 241	INMUNOGLOBULINA HUMANA
T32	DISO 278 298	ABORTO DE REPETICIÓN
T33	PROC 824 842	linfocitos totales
T34	PROC 467 511	consentimiento informado firmado por escrito
#24	AnnotatorNotes T34	C0811741; Obtain informed written consent; Health Care Activity
T35	PROC 747 769	Células NK citotóxicas
#25	AnnotatorNotes T35	C1504163; Natural killer (NK) cells, total count; Laboratory Procedure
T36	CHEM 1214 1230	inmunoglobulinas
#26	AnnotatorNotes T36	C0021027; Immunoglobulins; Amino Acid, Peptide, or Protein · Immunologic Factor
T37	DISO 1331 1334	VIH
#27	AnnotatorNotes T37	C0458074; Human immunodeficiency virus (HIV) status; Finding
T38	PROC 1415 1439	prueba de la hepatitis C
T39	Date 12 16	2014
T40	Route 67 78	INTRAVENOSA
#28	AnnotatorNotes T40	C1522726; Intravenous Route of Drug Administration; Functional Concept
T41	Route 242 253	INTRAVENOSA
#29	AnnotatorNotes T41	C1522726; Intravenous Route of Drug Administration; Functional Concept
T42	LIVB 598 606	paciente
#30	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T43	LIVB 610 617	Mujeres
#31	AnnotatorNotes T43	C0043210; Woman; Population Group
T44	Age 661 676	de 18 a 37 años
T45	Age 846 859	35 años o más
T46	Age 871 889	menores de 35 años
T47	LIVB 1039 1051	investigador
#32	AnnotatorNotes T47	C0035173; Research Personnel; Professional or Occupational Group
T48	Date 1252 1260	reciente
T50	Date 1455 1475	en el momento actual
T51	Date 1494 1514	en el momento actual
T52	Duration 1525 1545	los 12 meses previos
T53	PHYS 1676 1686	concepción
#33	AnnotatorNotes T53	C0009637; Conception; Organism Function | C0015914; Fertilization; Organism Function
T54	Duration 1690 1703	las 4 semanas
T55	CONC 1717 1730	primera dosis
T56	LIVB 1776 1788	investigador
#34	AnnotatorNotes T56	C0035173; Research Personnel; Professional or Occupational Group
T58	LIVB 1809 1817	paciente
#35	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	LIVB 1241 1251	bacteriana
#36	AnnotatorNotes T59	C0004611; Bacteria; Bacterium
T60	PHYS 1015 1026	comunicarse
#37	AnnotatorNotes T60	C2911692; Response (communication); Mental Process (?)
T61	PHYS 1058 1066	entender
#38	AnnotatorNotes T61	C0162340; Comprehension; Mental Process
T49	PROC 941 945	Peso
#39	AnnotatorNotes T49	C2985231; Body Weight Measurement; Diagnostic Procedure
T57	PROC 723 742	visita de selección
#40	AnnotatorNotes T57	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
A1	Assertion T17 Contraindicated
A2	Status T10 History_of
A3	Status T18 History_of
A4	Status T27 History_of
#41	AnnotatorNotes T31	C3537193; Human Immunoglobulin [EPC]; Pharmacologic Substance 
#42	AnnotatorNotes T4	C3537193; Human Immunoglobulin [EPC]; Pharmacologic Substance 
#43	AnnotatorNotes T3	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#44	AnnotatorNotes T33	C0200635; Lymphocyte Count measurement; Laboratory Procedure 
#45	AnnotatorNotes T12	C0200635; Lymphocyte Count measurement; Laboratory Procedure 
#46	AnnotatorNotes T14	C2363839; Natural killer T cell count; Laboratory Procedure (?)
#47	AnnotatorNotes T19	C0021051; Immunologic Deficiency Syndromes; Disease or Syndrome
#48	AnnotatorNotes T21	C0019163; Hepatitis B; Disease or Syndrome + C0019196; Hepatitis C; Disease or Syndrome
#49	AnnotatorNotes T38	C2363789; Hepatitis C virus test; Laboratory Procedure 
#50	AnnotatorNotes T50	C0521116; Current (present time); Temporal Concept 
#51	AnnotatorNotes T51	C0521116; Current (present time); Temporal Concept 
#52	AnnotatorNotes T27	C0085762; Alcohol abuse; Mental or Behavioral Dysfunction
#53	AnnotatorNotes T48	C0332185; Recent; Temporal Concept
T62	Spec_cue 1789 1795	puedan
T63	Observation 1822 1861	inapropiado para entrar en este estudio
A5	Assertion T63 Speculated
R1	Speculation Arg1:T62 Arg2:T63	
R2	Has_Quantifier_or_Qualifier Arg1:T58 Arg2:T63	
T64	Food 1486 1493	alcohol
#54	AnnotatorNotes T64	C0001967; Alcoholic Beverages; Food
R3	Has_Route_or_Mode Arg1:T4 Arg2:T40	
R4	Used_for Arg1:T4 Arg2:T1	
R5	Has_Route_or_Mode Arg1:T31 Arg2:T41	
R6	Used_for Arg1:T31 Arg2:T5	
T65	Quantifier_or_Qualifier 302 324	ETIOLOGÍA INMUNOLÓGICA
R7	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T65	
T66	Quantifier_or_Qualifier 415 437	etiologia inmunologica
R8	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T66	
R9	Before Arg1:T34 Arg2:T8	
R10	Before Arg1:T34 Arg2:T9	
R11	Experiences Arg1:T42 Arg2:T8	
R12	Experiences Arg1:T42 Arg2:T9	
R13	Experiences Arg1:T43 Arg2:T10	
T67	Quantifier_or_Qualifier 622 626	tres
R14	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T67	
A6	Status T67 History_of
R15	Has_Age Arg1:T43 Arg2:T44	
T68	Quantifier_or_Qualifier 647 659	consecutivos
#55	AnnotatorNotes T68	C1707491; Consecutive; Qualitative Concept
R16	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T68	
A7	Status T68 History_of
R17	Overlap Arg1:T57 Arg2:T44	
T69	Result_or_Value 813 842	13% de los linfocitos totales
R18	Has_Result_or_Value Arg1:T35 Arg2:T69	
R19	Has_Result_or_Value Arg1:T16 Arg2:T69	
R20	Overlap Arg1:T35 Arg2:T45	
R22	Overlap Arg1:T33 Arg2:T45	
T70	Result_or_Value 864 867	22%
R23	Has_Result_or_Value Arg1:T35 Arg2:T70	
R24	Has_Result_or_Value Arg1:T16 Arg2:T70	
R25	Overlap Arg1:T35 Arg2:T46	
T71	Result_or_Value 906 936	?10% de los linfocitos totales
R27	Has_Result_or_Value Arg1:T14 Arg2:T71	
R28	Has_Result_or_Value Arg1:T16 Arg2:T71	
T72	Result_or_Value 958 981	entre los 40 kg y 90 kg
R29	Has_Result_or_Value Arg1:T49 Arg2:T72	
T73	Observation 1002 1026	Capacidad de comunicarse
#56	AnnotatorNotes T73	C2364293; Able to communicate; Finding
T74	Observation 1002 1011;1053 1107	Capacidad para entender y cumplir con los requisitos del estudio
R30	Causes Arg1:T36 Arg2:T18	
R31	Causes Arg1:T59 Arg2:T20	
R32	Overlap Arg1:T20 Arg2:T48	
T75	Quantifier_or_Qualifier 1261 1287	clínicamente significativa
R33	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T75	
R34	Causes Arg1:T64 Arg2:T27	
T76	Result_or_Value 1367 1375	positivo
#57	AnnotatorNotes T76	C1446409; Positive; Finding
R35	Has_Result_or_Value Arg1:T22 Arg2:T76	
R36	Has_Result_or_Value Arg1:T24 Arg2:T76	
R40	Causes Arg1:T23 Arg2:T76	
R41	Overlap Arg1:T38 Arg2:T26	
R42	Overlap Arg1:T38 Arg2:T50	
R43	Overlap Arg1:T24 Arg2:T50	
R44	Overlap Arg1:T22 Arg2:T50	
R45	Overlap Arg1:T21 Arg2:T50	
R46	Overlap Arg1:T27 Arg2:T51	
R47	Has_Duration_or_Interval Arg1:T27 Arg2:T52	
T77	Observation 1547 1588	Participación en cualquier ensayo clínico
R50	Overlap Arg1:T53 Arg2:T54	
R51	Before Arg1:T53 Arg2:T55	
#58	AnnotatorNotes T75	C5209294; Clinical relevance; Intellectual Product
#59	AnnotatorNotes T32	C0000809; Abortion, Habitual; Disease or Syndrome
R49	Overlap Arg1:T69 Arg2:T45	
R52	Overlap Arg1:T70 Arg2:T46	
R21	Has_Result_or_Value Arg1:T38 Arg2:T76	
R26	Causes Arg1:T25 Arg2:T76	
R37	Experiences Arg1:T43 Arg2:T57	
R38	Overlap Arg1:T25 Arg2:T50	
R39	Overlap Arg1:T23 Arg2:T50	
#60	AnnotatorNotes T55	C5236155; Date of First Dose; Temporal Concept
#61	AnnotatorNotes T67	C0205449; Three; Quantitative Concept
A8	Experiencer T42 Patient
A9	Experiencer T43 Patient
A10	Experiencer T47 Other
A11	Experiencer T56 Other
A12	Experiencer T58 Patient
